EMA Withdrawn: Altargo (retapamulin) — Glaxo Group Ltd

View source ↗

Summary

The EMA withdrew Altargo (retapamulin) from the market for impetigo and staphylococcal skin infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Impetigo
• Staphylococcal Skin Infections

Drugs mentioned

• ALTARGO (retapamulin)

Snippet

Status: Withdrawn. Therapeutic area: Impetigo;Staphylococcal Skin Infections. MAH: Glaxo Group Ltd. Decision date: 09/11/2015